Novartis Exjade Trial Failed To Show Non-Inferiority To Desferal, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Subset analysis conducted by Novartis may show Exjade benefit in certain patients at higher doses, according to FDA background documents for the Sept. 29 Blood Products Advisory Committee meeting.